Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis

Vaccine

Volumn 31, Issue 27, 2013, Pages 2884-2890

  Ahn, So Shin ^a   Jeon, Bo Young ^b,c   Park, Seong Jeong ^a   Choi, Dong Hoon ^a   Ku, Sun Hwa ^b   Cho, Sang Nae ^b   Sung, Young Chul ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University Wonju   (South Korea)

Author keywords

Adjuvant; DNA vaccine; IL 7 nFc; Immunotherapy; Mtb32; Tuberculosis

Indexed keywords

BCG VACCINE; DEXAMETHASONE; DNA VACCINE; FC INTERLEUKIN 7 FUSION PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; MTB32 ANTIGEN; MYCOBACTERIUM ANTIGEN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE MODEL; DNA IMMUNIZATION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOSTIMULATION; LUNG ALVEOLUS CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG SYNERGISM; FEMALE; IMMUNOGLOBULIN FC FRAGMENTS; INTERFERON-GAMMA; INTERLEUKIN-7; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINATION; VACCINES, DNA;

EID: 84878470214     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.029     Document Type: Article

References (36)

1. Organization. WH. Global tuberculosis control: WHO report 2011. 2011; . http://www.who.int/tb/publications/global_report/en/.
2. Organization. WH. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. 2010; WHO/HTM/TB/2010.3.
3. Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 2007, 15(January (1)):7-13.
4. Skeiky Y.A., Lodes M.J., Guderian J.A., Mohamath R., Bement T., Alderson M.R., et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 1999, 67(August (8)):3998-4007.
5. Von Eschen K., Morrison R., Braun M., Ofori-Anyinam O., De Kock E., Pavithran P., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum Vaccine 2009, 5(July (7)):475-482.
6. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004, 172(June (12)):7618-7628.
7. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 2004, 72(November (11)):6622-6632.
8. Reed S.G., Coler R.N., Dalemans W., Tan E.V., DeLa Cruz E.C., Basaraba R.J., et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U.S.A. 2009, 106(February (7)):2301-2306.
9. Irwin S.M., Izzo A.A., Dow S.W., Skeiky Y.A., Reed S.G., Alderson M.R., et al. Tracking antigen-specific CD8T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 2005, 73(September (9)):5809-5816.
10. Ahn S.S., Jeon B.Y., Kim K.S., Kwack J.Y., Lee E.G., Park K.S., et al. Mtb32 is a promising tuberculosis antigen for DNA vaccination in pre- and post-exposure mouse models. Gene Ther 2012, 19(May (5)):570-575.
11. Ma A., Koka R., Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006, 24:657-679.
12. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009, 119(April (4)):997-1007.
13. Park S.H., Song M.Y., Nam H.J., Im S.J., Sung Y.C. Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys. Immune Netw 2010, 10(December (6)):198-205.
14. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144(February (4)):601-613.
15. Pellegrini M., Calzascia T., Elford A.R., Shahinian A., Lin A.E., Dissanayake D., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009, 15(May (5)):528-536.
16. Unsinger J., McGlynn M., Kasten K.R., Hoekzema A.S., Watanabe E., Muenzer J.T., et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 2010, 184(April (7)):3768-3779.
17. Maeurer M.J., Trinder P., Hommel G., Walter W., Freitag K., Atkins D., et al. Interleukin-7 or interleukin-15 enhances survival of Mycobacterium tuberculosis-infected mice. Infect Immun 2000, 68(May (5)):2962-2970.
18. Nam H.J., Song M.Y., Choi D.H., Yang S.H., Jin H.T., Sung Y.C. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. Eur J Immunol 2010, 40(February (2)):351-358.
19. Ahn SS, Jeon BY, Kim KS, Kwack JY, Lee EG, Park KS, et al. Mtb32 is a promising tuberculosis antigen for DNA vaccination in pre- and post-exposure mouse models. Gene Ther; Sep 29.
20. Ha S.J., Jeon B.Y., Kim S.C., Kim D.J., Song M.K., Sung Y.C., et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Ther 2003, 10(September (18)):1592-1599.
21. Ha S.J., Kim D.J., Baek K.H., Yun Y.D., Sung Y.C. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J Immunol 2004, 172(January (1)):525-531.
22. Betts M.R., Brenchley J.M., Price D.A., De Rosa S.C., Douek D.C., Roederer M., et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281(October (1-2)):65-78.
23. Sonnenberg M.G., Belisle J.T. Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. Infect Immun 1997, 65(November (11)):4515-4524.
24. Sable S.B., Plikaytis B.B., Shinnick T.M. Tuberculosis subunit vaccine development: impact of physicochemical properties of mycobacterial test antigens. Vaccine 2007, 25(February (9)):1553-1566.
25. Rivero-Lezcano O.M. Cytokines as immunomodulators in tuberculosis therapy. Recent Pat Antiinfect Drug Discov 2008, 3(November (3)):168-176.
26. Flynn J.L., Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001, 19:93-129.
27. Changhong S., Hai Z., Limei W., Jiaze A., Li X., Tingfen Z., et al. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene. Tuberculosis (Edinb) 2009, 89(January (1)):54-61.
28. Okada M., Kita Y., Nakajima T., Kanamaru N., Hashimoto S., Nagasawa T., et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009, 27(May (25-26)):3267-3270.
29. Melchionda F., Fry T.J., Milliron M.J., McKirdy M.A., Tagaya Y., Mackall C.L. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005, 115(May (5)):1177-1187.
30. Nanjappa S.G., Kim E.H., Suresh M. Immunotherapeutic effects of IL-7 during a chronic viral infection in mice. Blood 2011, 117(May (919)):5123-5132.
31. Chu Y.W., Memon S.A., Sharrow S.O., Hakim F.T., Eckhaus M., Lucas P.J., et al. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004, 104(August (4)):1110-1119.
32. Nanjappa S.G., Walent J.H., Morre M., Suresh M. Effects of IL-7 on memory CD8T cell homeostasis are influenced by the timing of therapy in mice. J Clin Invest 2008, 118(March (3)):1027-1039.
33. Rook G.A., al Attiyah R. Cytokines and the Koch phenomenon. Tubercle 1991, 72(March (1)):13-20.
34. Schluns K.S., Kieper W.C., Jameson S.C., Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8T cells in vivo. Nat Immunol 2000, 1(November (5)):426-432.
35. Vella A.T., Dow S., Potter T.A., Kappler J., Marrack P. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci U.S.A. 1998, 95(March (7)):3810-3815.
36. Mackall C.L., Fry T.J., Gress R.E. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11(May (5)):330-342.